Skip to main content

memo - Magazine of European Medical Oncology OnlineFirst articles

27.01.2022 | short review

Immunotherapy—another breakthrough in gastrointestinal malignancies

Immunotherapy is a breakthrough in different tumor entities. Recently, immunotherapy became an important treatment modality in gastrointestinal (GI) malignancies. In GI malignancies, immunotherapy with or without chemotherapy or targeted agents is …

Dr. Monika Lenzi, PhD PD Dr. Thomas Winder

21.01.2022 | short review Open Access

Tracking mutation and drug-driven alterations of oncokinase conformations

Numerous kinases act as central nodes of cellular signaling networks. As such, many of these enzymes function as molecular switches for coordinating spatiotemporal signal transmission. Typically, it is the compartmentalized phosphorylation of …

Andreas Feichtner, Valentina Kugler, Selina Schwaighofer, Thomas Nuener, Jakob Fleischmann, Dr. Eduard Stefan

21.01.2022 | case report

Systemic capillary leak syndrome following granulocyte colony-stimulating factor therapy in a T-lymphoblastic leukemia/lymphoma patient: a case report

SCLS is a rare and fatal angiopathy characterized by reversable protein leakage into the interstitial space leading to a classical triad of hypotension, hypoalbuminemia and hemoconcentration [ 1 ]. The exact incidence of SCLS is unknow since this …

Ahmed H. Al Sharie, Yazan O. Al Zu’bi, Sarah Al Sharie, Hawra A. Baydoun, Farah H. Atawneh, Osama Alshari, Dima Albals

14.01.2022 | short review

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

Agents targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) are part of systemic therapy in advanced colorectal cancer. It is well known that only certain molecular subpopulations profit from EGFR …

Johannes Schöche, Dora Niedersüß-Beke

04.01.2022 | case report

Palliative care: patient’s autonomy in the end-of-life situation

Palliative care has evolved over the past five decades as an interprofessional specialty to improve quality of life and quality of care for patients with cancer and their families. The main objective in an end-of-life (EOL) situation is to …

MD Bert Engelhardt

23.12.2021 | short review Open Access

Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer

Antibody–drug conjugates (ADCs) against numerous molecular targets are currently being developed for the treatment of breast cancer (BCa). While the first ADC directed against Her2, namely trastuzumab–emtansine, was approved several years ago …

Maximilian Marhold

22.12.2021 | short review

Practice-changing strategies in the treatment of esophageal cancer

For patients suffering from localized and advanced stage esophageal cancer, long-term outcomes remain poor. However, as already seen in other tumors, the introduction of immune checkpoint inhibitors has led to practice-changing results in the …

MD Ercan Müldür, MD Wolfgang Hilbe

22.12.2021 | short review Open Access

Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?

In recent years, treatment of patients exhibiting chronic lymphocytic leukemia has changed extensively due to advances in the development of targeted therapies. The Bcl‑2 inhibitor venetoclax demonstrated outstanding results when used in mono- as …

Katharina T. Prochazka, Barbara Uhl

22.12.2021 | short review

New targeted therapies in kidney cancer

New agents and combinations continue to change the clinical practice of treating patients with renal cell carcinoma. In this review we want to highlight the most recent therapeutic developments and also give an overview of the current standard of …

MD Karl Mayrhofer, MD, MBA Dora Niedersüß-Beke

20.12.2021 | short review

BTKi, venetoclax, obinutuzumab: what is the ideal combination?

Chronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Currently, patients are mostly treated with so-called novel agents, including Bruton tyrosin kinase (BTK) inhibitors and BCL‑2 …

MD Daniel Heintel

09.12.2021 | original report

The outcome of COVID-19 in patients with hematological malignancy

Coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO) on 11 March 2020 [ 1 ]. Patients with comorbidities such as hypertension (HT), cardiovascular disease, diabetes mellitus (DM), chronic …

Pınar Tığlıoğlu, Murat Albayrak, Mesut Tığlıoğlu, Hacer Berna Afacan Öztürk, Merih Reis Aras, Buğra Sağlam, Senem Maral

24.11.2021 | short review Open Access

Clinical challenges in the management of endocrine side effects of immuno-oncological therapies

Given the growing use of immune checkpoint inhibitor (ICI) therapy in oncology, the prevalence of endocrine side effects is rapidly increasing. As clinicians are nowadays frequently confronted with these side effects in routine clinical care …

Peter Wolf, Thomas Scherer

22.11.2021 | original report

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

Multiple myeloma (MM) is a malignant B‑cell disorder characterized by heterogeneous cytogenetic abnormalities, resulting in a wide heterogeneity in survival outcomes [ 1 , 2 ]. Although treatment strategies for MM have improved in the last decade …

Xiao Xiao, Xinchen Fang, Wen Yao, Zhu Huaiping

04.11.2021 | short review Open Access

Cardiotoxicity—current recommendations of prevention and treatment

Tremendous advances in modern oncology therapies enable an increasing life expectancy of many cancer entities. Short or long-term cardiovascular side effects, however, gain importance. The current review focuses on recent recommendations for …

MD, FESC, FEACVI, FHFA A.o. Univ. Prof. Jutta Bergler-Klein

26.10.2021 | case report

Chronic myeloid leukemia associated with acquired von Willebrand syndrome: A case report

We report the case of a 64-year-old man with CML in the chronic phase that was originally diagnosed in 2014. His past investigations at the time of diagnosis of CML in the chronic phase revealed the following: baseline CBC-Hb 9.9 g/dl, TLC …

MD Dr. Prachi Mohapatra, MD Dr. Satya Prasad Mahapatra

19.10.2021 | short review Open Access

Innovative strategies in metastatic gastric cancer: a short review

Recent innovative advances, especially concerning immunotherapeutic agents and targeted therapies, have changed the face of modern oncology. The year 2020 represents a milestone in the treatment of gastroesophageal cancer because several trials …

MD Hannah Christina Puhr, MD PhD Aysegul Ilhan-Mutlu

06.10.2021 | short review Open Access

Checkpoint inhibitor pneumonitis: Short review of literature and case report

Immune checkpoint blockade (ICB) has fundamentally improved the treatment landscape of advanced lung cancer. Improved tolerability and encouraging duration of response in selected patients are some of the advantages of ICB over conventional …

MD, PhD Romana Elisabeth Wass, MD, PhD David Lang, MD Andreas Horner, MD Bernd Lamprecht

05.10.2021 | short review Open Access

New actionable targets and investigational drugs in chronic lymphocytic leukemia

The treatment landscape of chronic lymphocytic leukemia (CLL) has shifted from chemotherapy-based approaches to targeted agents in the last decade. However, evolving drug resistance and accumulating toxicity remain challenges that still limit …

M.D., PhD Jan-Paul Bohn

09.09.2021 | case report Open Access

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

We present a case of a male patient with advanced hepatocellular carcinoma who developed hepatic and dermatological immune-related adverse events during treatment with the immune checkpoint inhibitor nivolumab. We discuss relevant aspects …

MD Bernhard Scheiner, MD PhD Matthias Pinter

08.09.2021 | review Open Access

Neoadjuvant versus adjuvant management of resectable pancreas cancer: A review of the literature

Neoadjuvant therapy is well-accepted in the treatment of borderline resectable and locally advanced PC, the benefit of neoadjuvant chemotherapy in patients with resectable disease, however, is currently not so clear. Here we provide an up date on …

PD OA Konstantin Schlick